IBDEI2GM ; ; 17-FEB-2016
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,41717,1,4,0)
 ;;=4^G90.59
 ;;^UTILITY(U,$J,358.3,41717,2)
 ;;=^5004171
 ;;^UTILITY(U,$J,358.3,41718,0)
 ;;=G56.01^^159^2010^12
 ;;^UTILITY(U,$J,358.3,41718,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41718,1,3,0)
 ;;=3^Carpal Tunnel Syndrome,Right Upper Limb
 ;;^UTILITY(U,$J,358.3,41718,1,4,0)
 ;;=4^G56.01
 ;;^UTILITY(U,$J,358.3,41718,2)
 ;;=^5004018
 ;;^UTILITY(U,$J,358.3,41719,0)
 ;;=G56.02^^159^2010^11
 ;;^UTILITY(U,$J,358.3,41719,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41719,1,3,0)
 ;;=3^Carpal Tunnel Syndrome,Left Upper Limb
 ;;^UTILITY(U,$J,358.3,41719,1,4,0)
 ;;=4^G56.02
 ;;^UTILITY(U,$J,358.3,41719,2)
 ;;=^5004019
 ;;^UTILITY(U,$J,358.3,41720,0)
 ;;=G56.21^^159^2010^56
 ;;^UTILITY(U,$J,358.3,41720,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41720,1,3,0)
 ;;=3^Lesion of Ulnar Nerve,Right Upper Limb
 ;;^UTILITY(U,$J,358.3,41720,1,4,0)
 ;;=4^G56.21
 ;;^UTILITY(U,$J,358.3,41720,2)
 ;;=^5004024
 ;;^UTILITY(U,$J,358.3,41721,0)
 ;;=G56.22^^159^2010^55
 ;;^UTILITY(U,$J,358.3,41721,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41721,1,3,0)
 ;;=3^Lesion of Ulnar Nerve,Left Upper Limb
 ;;^UTILITY(U,$J,358.3,41721,1,4,0)
 ;;=4^G56.22
 ;;^UTILITY(U,$J,358.3,41721,2)
 ;;=^5004025
 ;;^UTILITY(U,$J,358.3,41722,0)
 ;;=M26.60^^159^2010^180
 ;;^UTILITY(U,$J,358.3,41722,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41722,1,3,0)
 ;;=3^Temporomandibular Joint Disorder,Unspec
 ;;^UTILITY(U,$J,358.3,41722,1,4,0)
 ;;=4^M26.60
 ;;^UTILITY(U,$J,358.3,41722,2)
 ;;=^5011714
 ;;^UTILITY(U,$J,358.3,41723,0)
 ;;=L40.52^^159^2010^137
 ;;^UTILITY(U,$J,358.3,41723,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41723,1,3,0)
 ;;=3^Psoriatic Arthritis Mutilans
 ;;^UTILITY(U,$J,358.3,41723,1,4,0)
 ;;=4^L40.52
 ;;^UTILITY(U,$J,358.3,41723,2)
 ;;=^5009167
 ;;^UTILITY(U,$J,358.3,41724,0)
 ;;=L40.53^^159^2010^138
 ;;^UTILITY(U,$J,358.3,41724,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41724,1,3,0)
 ;;=3^Psoriatic Spondylitis
 ;;^UTILITY(U,$J,358.3,41724,1,4,0)
 ;;=4^L40.53
 ;;^UTILITY(U,$J,358.3,41724,2)
 ;;=^5009168
 ;;^UTILITY(U,$J,358.3,41725,0)
 ;;=M32.9^^159^2010^179
 ;;^UTILITY(U,$J,358.3,41725,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41725,1,3,0)
 ;;=3^Systemic Lupus Erythematosus,Unspec
 ;;^UTILITY(U,$J,358.3,41725,1,4,0)
 ;;=4^M32.9
 ;;^UTILITY(U,$J,358.3,41725,2)
 ;;=^5011761
 ;;^UTILITY(U,$J,358.3,41726,0)
 ;;=M32.0^^159^2010^175
 ;;^UTILITY(U,$J,358.3,41726,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41726,1,3,0)
 ;;=3^Systemic Lupus Erythematosus,Drug-Induced
 ;;^UTILITY(U,$J,358.3,41726,1,4,0)
 ;;=4^M32.0
 ;;^UTILITY(U,$J,358.3,41726,2)
 ;;=^5011752
 ;;^UTILITY(U,$J,358.3,41727,0)
 ;;=M32.13^^159^2010^177
 ;;^UTILITY(U,$J,358.3,41727,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41727,1,3,0)
 ;;=3^Systemic Lupus Erythematosus,Lung Involvement
 ;;^UTILITY(U,$J,358.3,41727,1,4,0)
 ;;=4^M32.13
 ;;^UTILITY(U,$J,358.3,41727,2)
 ;;=^5011756
 ;;^UTILITY(U,$J,358.3,41728,0)
 ;;=M32.14^^159^2010^176
 ;;^UTILITY(U,$J,358.3,41728,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41728,1,3,0)
 ;;=3^Systemic Lupus Erythematosus,Glomerular Disease
 ;;^UTILITY(U,$J,358.3,41728,1,4,0)
 ;;=4^M32.14
 ;;^UTILITY(U,$J,358.3,41728,2)
 ;;=^5011757
 ;;^UTILITY(U,$J,358.3,41729,0)
 ;;=M32.12^^159^2010^178
 ;;^UTILITY(U,$J,358.3,41729,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41729,1,3,0)
 ;;=3^Systemic Lupus Erythematosus,Pericarditis
 ;;^UTILITY(U,$J,358.3,41729,1,4,0)
 ;;=4^M32.12
 ;;^UTILITY(U,$J,358.3,41729,2)
 ;;=^5011755
 ;;^UTILITY(U,$J,358.3,41730,0)
 ;;=M05.59^^159^2010^159
 ;;^UTILITY(U,$J,358.3,41730,1,0)
 ;;=^358.31IA^4^2
